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     INTRODUCTION 
  Over the past four decades, dengue disease has become 
recognized as the world’s most important mosquito-borne 
viral disease, emerging in countries previously considered 
free of disease and reemerging in countries where the dis-
ease was once controlled.  1,  2   Inadequate mosquito control 
and increasing urbanization and air travel have placed an 
estimated 3 billion inhabitants of the world’s tropical areas 
and roughly 120 million travelers at risk of dengue infection 
each year.  2–  5   Globally, the projected number of annual den-
gue infection cases is 50–100 million, with approximately 
24,000 deaths, mainly in children, and an estimated annual 
burden of 750,000 disability-adjusted life years (DALYs).  3,  5–  10  
About 36 million symptomatic cases are estimated to occur 
annually.  11  
  The case of the Americas is of special interest. From the 
1950s to the 1970s, the Americas were a virtually dengue-free 
zone because of the eradication of   Aedes aegypti   (the principal 
vector of dengue in this continent) in a continent-wide vector 
control campaign. Combined with the campaign’s interruption 
in the early 1970s, the acceleration of uncontrolled urbaniza-
tion with its associated waste management problems in many 
Latin American cities contributed to the extensive distribution 
of   Ae. aegypti   and the return of dengue virus circulation.  1,  7,  12–  15  
During the last two decades, all tropical areas of Central and 
South America, as well as most of the Caribbean, have expe-
rienced a sharp increase in the incidence of both dengue fever 
(DF) and dengue hemorrhagic fever (DHF): almost 3 million 
dengue cases were officially reported in the Americas for the 
period of 2001–2005 compared with 2.1 million cases for the 
period of 1995–1999.  14,  16–  18  
  Dengue ranks fifth in the list of neglected tropical diseases 
in the Americas in terms of DALYs.  19   However, with weak, 
passive surveillance systems, the true burden may be underes-
timated. Serological surveys suggest the occurrence of millions 
of dengue infections annually in the region.  9,  14,  20–  23  Additionally, 
epidemic dengue occurs cyclically every 3–5 years, with evi-
dence suggesting an increase in the magnitude and severity of 
cases with each new epidemic.  2,  9,  24,  25  
  The few economic and social evaluations of dengue pub-
lished to date provide empirical estimates for only one or a 
small number of countries, and comparisons are limited by 
important methodological differences.  4,  9,  26–  35  The cost of dengue 
has not been estimated at the scale of the American continents. 
Such estimates, which are available for several other vaccine-
preventable diseases, are useful for developers of drugs, vac-
cines, insecticides, and novel insect control approaches as well 
as international donors and national governments to prioritize 
their efforts.  36–  39   To help address this need, this paper estimates 
of the economic costs and DALYs lost because of this disease 
in the Americas. 
   MATERIALS AND  METHODS 
  Five major components are needed for estimating the eco-
nomic and disease burden of a disease from a societal perspec-
tive: (1) the number of reported dengue cases, (2) the degree 
of underreporting, (3) the direct and indirect costs per case, (4) 
the DALY burden per case, and (5) the country’s demographic 
information. 
  Reported  dengue  cases.     The number of dengue cases 
was obtained from the Pan American Health Organization 
(PAHO), the regional body of the World Health Organization 
(WHO) responsible for the 35 nations and 9 territories of the 
Americas.  16   Dengue is subject to important year to year vari-
ations in incidence. To stabilize the projections, estimations 
reported in this paper were based on the average of DF, DHF, 
and fatal cases reported over the period of 2000–2007 under 
the PAHO case definition.  18  
  Countries were divided into six subregions: North America 
(United States of America and Canada), Central America and 
Mexico, the Andean region (Bolivia, Colombia, Ecuador, Peru, 
and Venezuela), Brazil, the Southern cone (Argentina, Chile, 
Paraguay, and Uruguay), and the Caribbean region. Reported 
dengue cases (DF and DHF) are presented in   Figure 1  . 
    The age distribution of cases, required for the estimation of 
DALYs and indirect cost of deaths, was available for Brazil, 
Mexico, Costa Rica, El Salvador, Honduras, Colombia, and 
Venezuela. For other countries in these three subregions, we 
applied the average country proportions from each subre-
gion. For the three subregions with no country-specific infor-
mation (Caribbean region, North America, and Southern 
cone), the average of all seven countries with available data 
was used. 
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   Dengue  surveillance  and  underreporting.    Routine  surveil-
lance systems do not capture all dengue cases.  20   To  estimate 
the actual number of cases, reported cases need to be mul-
tiplied by a correction or expansion factor (EF), which rep-
resents the degree of underreporting.  40   We identified five 
field studies in four American countries that provided suf-
ficient information to estimate the underreporting rate 
( Table 1 ). Reporting of hospitalized cases (the severest cases) is 
relatively complete (range = 1.4–3.4).  41–  43   Reporting of milder, 
ambulatory cases is less complete. In a study in Nicaragua, 
combining all types of dengue cases, the EF ranged from 14 
to 28.  44   In addition to these five field studies, other authors 
provide estimates of underreporting. Luz and others  45   recom-
mended EFs for Brazil ranging from 1 to 10 for endemic years 
and from 0.3 to 10 for epidemic years using uniform distribu-
tions (central values = 5.5 and 5.15). Armien and others  27   used 
an EF of 6 in estimating the costs of Panama’s 2005 dengue epi-
demic. Meltzer and others  35   used an EF of 10 for 0- to 15-year-
old children and an EF of 27 for older children and adults in 
Puerto Rico. 
            We defined two EFs per country—one (EF1) for hospital-
ized and fatal cases and a second (EF2) for cases managed 
entirely in an ambulatory setting—and applied extensive sen-
sitivity analyses to account for the uncertainty of these estima-
tions. In countries with empirical estimates, EFs were defined 
in accordance with existing data. EF1 was set at 1.6 (range = 
1.4–3.0) for Brazil, 2.3 (range = 1.4–3.3) for Colombia, Panama, 
and Nicaragua, and 2.4 (range = 2.3–3.4) for Puerto Rico. EF2 
was set at 5 (range = 2.1–10) for Brazil, 9 (range = 4.5–18) 
for Colombia, 20.4 (range = 16–28) for Nicaragua, 6 (range = 
3–12) for Panama, and 15 (range = 10–27) for Puerto Rico. In 
countries without empirical estimates, we used average expan-
sion factors of 2.3 (range = 1.4–3.3) for EF1 and 15 (range = 
9–28) for EF2. 
   Dengue  costs  per  case.     We conducted a systematic litera-
ture review for articles on dengue costs published through 
December 2009 using PubMed with keywords dengue and eco-
nomics. From the 48 articles retrieved, 8 articles provided data 
covering nine locations in the Americas: Argentina,  30   Brazil, 4  
Cuba,  9,  28,  31   El Salvador,  4   Guatemala, 4   Nicaragua, 9   Panama, 4,  27  
Puerto Rico,  9,  32   and  Venezuela. 4,  26   We also included a recent 
study about Puerto Rico presented at an international confer-
ence.  46   Methodological variability limits the comparability of 
the data. Three studies were retrospective analyses of the costs 
of a large epidemic.  28,  31,  32   Three other studies retrospectively 
estimated costs of infections from official records.  26,  29,  30   One of 
these publications is a literature review,  9   and two publications 
share cost data for Panama.  4,  27  
  The review found that available cost data were very lim-
ited. Also, the studies varied in approach and scope and were 
impacted by differences among the countries’ health systems 
and economies.  47,  48   To develop consistent and comprehensive 
estimates, we needed to rely on studies that included both 
direct and indirect costs and funding from all sources (house-
holds, governments, and employers). Our analysis, therefore, 
focused on the results of two prospective cost studies for cost 
per dengue case: a large study with data corresponding to the 
year 2005 for Brazil, El Salvador, Guatemala, Panama, and 
Venezuela and a study performed in 2009 in Puerto Rico—
conducted with similar methods as source countries.  4,  46   Both 
studies documented direct medical, direct non-medical, and 
indirect costs of dengue cases treated in hospital or ambu-
latory settings. For these six source countries, we updated 
the originally reported costs to 2010 US dollars (US$) using 
International Monetary Fund (IMF) statistics.  49   For all other 
(target) countries, we used the average costs observed in 
source countries corrected for differences in purchasing power 
and cost structure (  Figure 2  ). 
    We corrected for international differences in medical 
costs using the WHO      -CHOosing Interventions that are Cost 
 Figure 1.        Number of dengue reported cases in the Americas from 
2000  to  2007.    
 Table 1 
    Sensitivity of dengue surveillance systems in American countries and corresponding expansion factors   
Study Country Period Type of dengue case Method Expansion factors
Duarte and 
Franca  42 
Brazil 1996–2002 Hospitalized 
dengue case
Sensitivity of the surveillance system 
using hospital records as the reference
Overall = 1.6 (1.4–1.8); DHF = 1.4 
(1.3–1.5); DF = 2.1 (1.6–3.0)
Camacho and 
others  63 
Colombia 1995–1997 All types of 
dengue cases
Sensitivity of the surveillance system 
using emergency room medical 
records as the reference
Overall = 9
Standish and 
others  44 
Nicaragua 2004–2008 All types of 
dengue cases
Comparison of incidence obtained 
through active surveillance with 
reported incidence in the same area
Clinically diagnosed: 20.4 (2004–2008), 
16 (2007–2008), 28 (2005–2006); 
lab-confirmed: 23.1 (2004–2008), 
14 (2006–2007), 28 (2005–2006)
Dechant and 
Rigau-Perez  41 
Puerto Rico 1991–1995 Hospitalized 
dengue case
Capture–recapture method 1991–1995 = 2.4; 1991 = 2.3; 1993 = 3.4
Rigau-Perez  43 Puerto  Rico 1988–1997 Hospitalized 
dengue case
Sensitivity and specificity of the 
surveillance system compared 
with hospital records
Overall = 3
    Figures in parentheses correspond to 95% confidence intervals assuming a binomial distribution for sensitivity analysis.   202 SHEPARD AND OTHERS
Effective (CHOICE) database.  50   For hospital cases, the cor-
rection factor was based on the cost per hospitalization day, 
and for ambulatory cases, the correction factor was based on 
the cost per consultation in health centers (ratio of costs in 
target and source countries expressed in 2010 international 
dollars [I$]). Indirect costs were corrected for differences in 
income using the ratio of income per capita (expressed in I$) 
calculated using IMF statistics.  49   Direct non-medical costs 
were corrected only for differences in purchasing power. 
Uncertainty in cost per dengue was accounted for by using the 
standard deviations observed in the multicountry cost study.  4  
We, therefore, assumed that cost per case followed a normal 
distribution, with coefficients of variation of 51% for ambu-
latory cases and 78% for hospitalized cases. All final results 
were expressed both in 2010 US$ and 2010 I$. 
  Consistent with reported observations, we considered that 
all DHF cases are treated in an inpatient hospital setting and 
that most (i.e., 90%; range = 80–100% in sensitivity analyses) 
DF cases are managed in an ambulatory setting.  4  The economic 
cost of deaths was estimated using the human capital approach 
based on productivity losses.  51   For each dengue death, the 
number of discounted life years lost was based on the age dis-
tribution of dengue deaths and remaining life expectancy at 
those ages in each country, which was obtained from WHO life 
tables.  52   Productivity losses were calculated by weighting the 
discounted life years lost by the country-specific gross domes-
tic product (GDP)       per capita and using a 3% discount rate.  49  
Finally, the total cost of dengue illness in each country was 
obtained by combining data on unit cost per case with the cor-
responding number of cases corrected for underreporting. 
   DALY  calculations.     Disease burden was expressed in terms 
of standard DALYs and calculated in accordance with meth-
ods developed by WHO.  53   The total number of years of life 
lost because of dengue-related death was estimated using the 
age distribution of dengue cases and age- and country-specific 
mortality rates.  52   In accordance with previous studies, disabil-
ity during non-fatal dengue cases was accounted for consider-
ing an average duration of 14 days for DHF (range = 10–18) 
and 4.5 days for DF (range = 2–7) and a disability weight of 
0.81 for both DF and DHF.  35,  45,  54  
   Demographic  data.     Results are presented both in absolute 
numbers and per unit of population (cases per 1,000 people and 
cost per capita). In all cases, we considered the entire popula-
tion of the area under consideration for the results expressed 
per unit of population. Demographic data were drawn from 
international statistical databases of the US Census Bureau.  55  
   Sensitivity  analyses.     The range of variation of the results of 
our analysis was assessed using probabilistic sensitivity analy-
sis,  54   including four categories of parameters: (1) the expan-
sion factors (EF1 and EF2) with an associated distribution of 
triangular form based on country-specific values, (2) the pro-
portion of DF cases treated in a hospital setting with a distri-
bution of triangular form (mode = 10%; range = 0–20%), (3) 
the cost per dengue case using normal distribution with coef-
ficients of variation of 51% for ambulatory cases and 78% for 
hospitalized cases, and (4) the duration of DF (range = 2–7 
days) and DHF cases (range = 10–18 days) with an associ-
ated uniform distribution.  45   For each sensitivity analysis, 5,000 
Monte Carlo simulations were performed, with independent 
drawing for each parameter and each country. Results are pre-
sented as median values and 95% confidence intervals. 
    RESULTS 
  The estimated average annual number of dengue cases 
for the 2000–2007 period adjusted for underreporting is 
5.6 million (  Table 2  ). Following variations in reported cases, 
yearly projected numbers varied 3-fold, ranging from 2.6 mil-
lion cases in 2004 to 7.8 million cases in 2007. Of these, there 
were an estimated 33,692 DHF cases (representing less than 
1%) and an average of 453 deaths per year. Brazil contrib-
uted the highest number of cases (2.1 million; i.e., 39% of the 
total number of cases). Four of the six regions (Brazil, Andean 
region, Central America and Mexico, and the Caribbean) had 
similarly high incidence rates of about 1% per year. 
            The total cost per ambulatory case ranged from US$72 
(Cuba) to US$2,300 (Bermuda), with a median value of 
US$472, whereas the total cost per hospitalized case ranged 
 Figure 2.        Method used for estimating cost of non-fatal dengue 
cases in all American countries.       
 Table 2 
     Projected annual number of dengue cases in the Americas (2000–2007)  *     
Area DF DHF Deaths Cases per 1,000  † 
North America 1,692 (1,086–2,570) 0 (0–0) 0 (0–0) 0.005 (0.003–0.008)
Central America and Mexico 1,232,690 (1,002,139–1,490,177) 10,845 (8,623–13,123) 78 (66–89) 8.962 (7.28–10.83)
Andean subregion 1,621,678 (1,241,826–2,096,319) 20,173 (15,664–24,783) 100 (77–125) 13.715 (10.5–17.72)
Brazil 2,166,060 (1,109,386–3,464,314) 1,690 (1,295–2,422) 120 (92–172) 11.449 (5.87–18.31)
Southern cone  ‡  137,305 (92,782–201,479) 16 (11–21) 5 (3–7) 2.198 (1.49–3.23)
Caribbean 448,412 (381,315–524,059) 904 (779–1,036) 150 (122–179) 11.585 (9.85–13.54)
The Americas 5,607,836 (3,828,533–7,778,918) 33,628 (26,372–41,384) 453 (362–572) 6.355 (4.34–8.81)
    Note that the intervals in parentheses show 95% confidence intervals.   
    *     Annual average calculated over the 2000–2007 period.   
    †     DF + DHF cases per 1,000 people.   
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from US$306 in Nicaragua to US$17,803 in the United States 
(median value = US$1,227) (  Table 3  ). The share of ambulatory 
case costs because of direct costs varies substantially between 
countries (e.g., 17% in Brazil and 95% in Puerto Rico). For 
most countries, the proportion of cost per case because of 
direct costs is higher for hospitalized cases than for ambula-
tory cases. 
      The  aggregate  annual  total  cost  of  dengue  in  the  Americas 
for the period 2000–2007 was US$2.1 billion. When uncer-
tainty on parameters values was incorporated, the estimate 
ranged from US$1–4 billion. Ambulatory cases accounted for 
72.9% of the total costs overall, but the ambulatory share var-
ied by 45.5% in North America (but over 60% in the five oth-
ers subregions). About 60% of dengue costs in the Americas 
correspond to indirect costs. Most of these indirect costs are 
related to productivity losses induced by non-fatal dengue 
cases. Deaths accounted for only a small proportion (2.6%) of 
total costs of the disease. 
 The geographic and temporal distribution of costs paralleled 
the distribution in numbers of reported cases. Geographically, 
Brazil alone accounted for 40.9% of the total cost of dengue, 
followed by the Andean region with 25.1%, Central America 
 Table 3 
    Estimated average cost per dengue case by country and setting in 2010 US$   
Country
Ambulatory cases Hospitalized cases
Direct medical Direct non-medical Indirect Total cost Direct medical Direct non-medical Indirect Total cost
Andean subregion
Bolivia $95 $10 $51 $155 $143 $111 $137 $392
Colombia $66 $11 $108 $185 $353 $128 $291 $772
Ecuador $127 $11 $97 $235 $251 $125 $262 $638
Peru $132 $11 $116 $259 $288 $123 $312 $723
Venezuela *  $118 $18 $194 $331 $864 $64 $310 $1,238
Central America
Belize $239 $13 $115 $367 $387 $144 $311 $842
Costa Rica $279 $14 $174 $467 $503 $157 $469 $1,129
El Salvador  *  $27 $2 $77 $107 $289 $170 $99 $559
Guatemala *  $24 $10 $78 $111 $304 $155 $72 $531
Guyana $43 $9 $44 $95 $174 $98 $118 $389
Honduras $52 $12 $60 $124 $179 $135 $161 $475
Mexico $264 $13 $209 $486 $502 $144 $563 $1,209
Nicaragua $108 $9 $27 $144 $133 $100 $74 $306
Panama *  $78 $25 $313 $416 $514 $419 $404 $1,336
Suriname $92 $17 $172 $281 $435 $193 $463 $1,091
North America
Canada $360 $22 $963 $1,345 $2,036 $243 $2,599 $4,878
United States of America $401 $23 $1,186 $1,610 $14,350 $254 $3,199 $17,803
Southern cone
Argentina $279 $12 $202 $493 $617 $138 $545 $1,300
Brazil *  $49 $18 $317 $383 $381 $47 $460 $889
Chile $259 $12 $207 $478 $523 $136 $557 $1,216
Paraguay $55 $11 $62 $128 $218 $127 $167 $512
Uruguay $314 $15 $244 $574 $601 $170 $659 $1,430
The Caribbean
Antigua and Barbuda $274 $18 $390 $682 $762 $199 $1,051 $2,012
Bahamas $336 $19 $553 $907 $1,198 $208 $1,491 $2,897
Barbados $297 $18 $380 $695 $940 $199 $1,026 $2,164
Cuba $26 $7 $39 $72 $134 $76 $106 $317
Dominica $213 $12 $145 $370 $325 $134 $390 $849
Dominican Republic $80 $15 $145 $239 $391 $162 $391 $944
French Guiana $421 $27 $300 $749 $2,346 $305 $810 $3,460
Guadeloupe $421 $27 $289 $737 $2,346 $305 $779 $3,430
Martinique $421 $27 $520 $968 $2,346 $305 $1,402 $4,052
Grenada $251 $13 $170 $434 $408 $151 $459 $1,018
Haiti $125 $14 $21 $160 $98 $155 $57 $311
Jamaica $71 $14 $127 $212 $289 $162 $342 $792
Aruba $420 $26 $734 $1,180 $2,500 $291 $1,980 $4,771
Curaçao $420 $26 $520 $966 $2,500 $291 $1,402 $4,193
Saint Kitts and Nevis $352 $17 $271 $640 $663 $193 $730 $1,586
Saint Lucia $237 $13 $162 $412 $361 $148 $437 $947
St. Vincent and Grenadines $74 $13 $157 $244 $377 $147 $424 $948
Trinidad and Tobago $505 $21 $530 $1,057 $1,183 $240 $1,430 $2,853
Anguilla $334 $21 $1,052 $1,408 $1,929 $236 $2,839 $5,004
Bermuda $334 $21 $1,944 $2,300 $1,929 $236 $5,246 $7,411
British Virgin Islands $334 $21 $1,052 $1,408 $1,929 $236 $2,839 $5,004
Cayman Islands $334 $21 $1,206 $1,561 $1,929 $236 $3,253 $5,418
Montserrat $334 $21 $1,052 $1,408 $1,929 $236 $2,839 $5,004
Turks and Caicos Islands $334 $21 $1,052 $1,408 $1,929 $236 $2,839 $5,004
American Virgin Islands $118 $23 $429 $569 $4,207 $254 $1,157 $5,618
Puerto Rico  *  $498 $27 $30 $555 $1,764 $124 $2,939 $4,827
    *     Countries with available information on cost per case.   204 SHEPARD AND OTHERS
and Mexico with 17.7%, and the Caribbean with 15.0%. The 
Southern cone accounted for only 1.2% of the cost, and North 
America was less than 0.3%. When countries are considered 
individually, two additional countries stand out as major con-
tributors to the dengue economic burden in the Americas: 
Venezuela (15%) and Mexico (7%). When costs were calcu-
lated separately by year, the annual cost of dengue ranged 
from $0.9 billion in a low incidence year (2004) to $3.1 billion 
in a high incidence year (2007) (  Figure 3  ). 
    The two categories of parameters having the strongest 
impact on the variation of total dengue costs (  Figure 4  ) in sen-
sitivity analyses are (1) the cost per case of ambulatory cases, 
which generate a variation of total dengue costs from −55% 
to +55% and (2) the expansion factors for DF associated with 
a range of −33% to +40% of total dengue costs. This result is 
consistent with the fact that ambulatory cases are responsible 
for the major part of dengue economic burden. 
    The estimated cost per capita was highest in the four regions 
with the highest dengue annual incidence (about 1%), ranging 
from US$2.74 in Central America to US$8.29 in the Caribbean 
( Table  4 ). 
            The estimated number of DALYs lost each year for the 
entire region ranged from 45,080 to 115,874, with a median 
value of 72,277 (  Table 4  ). Interestingly, the gap between Brazil 
and other areas is slightly lower when considering this crite-
rion for assessing dengue burden, with 36% of the DALYs 
lost in Brazil, 28% in the Andean region, and 21% in Central 
America and Mexico. This result is mainly related to the num-
ber of deaths per dengue case (case fatality rate), which, in 
Brazil, is below the American average (5/100,000 versus 
8/100,100). The number of DALYs per million inhabitants is 
50–131 for the Americas as a whole or 90–233 if only the four 
regions at high dengue risk are considered. 
  The use of international dollars did not substantially modify 
the rank across regions (  Table 5  ): Brazil remains the country 
where the cost of dengue is highest (42% of the total burden), 
and the Caribbean remains the area with the highest cost per 
capita (I$8.70). Aggregate costs in I$ are generally higher 
than their counterparts in US$, reflecting the differences in 
purchasing power between the United States and most of the 
American countries in which dengue is highly endemic. For 
example, aggregate costs for the Americas are I$3.2 billion 
(  Table 5  ) compared with US$2.1 billion (  Table 4  ). 
        DISCUSSION 
  Our analysis, combining available information on reported 
cases, levels of underreporting, and cost per case, shows that 
the annual economic burden of dengue in the Americas is sub-
stantial and subject to important year to year variation. About 
60% of these costs are because of productivity losses (indi-
rect costs), which affect households, employers, and govern-
ments. Brazil is the country with highest number of cases and 
highest cost, but the economic impact of dengue is substan-
tial in many American countries, with a cost per capita greater 
than US$2 in four of the six American subregions considered 
(Andean region, Brazil, the Caribbean, and Central America 
and Mexico). 
  To our knowledge, this is the first assessment of the total 
cost of dengue illness for the Americas. Estimates have, how-
ever, been published for selected countries. Armien and oth-
ers  27   calculated that in 2005, a large epidemic year, dengue cost 
Panama about US$16 million. Our estimate for Panama is lower 
(about US$5 million), but our reference period differs (annual 
average over the 2000–2007 period), and unlike Armien and 
others,  27  we did not include the cost of vector control efforts. Our 
estimate for Cuba is also lower than data reported by Guzman 
and others,  28   but their report examined a year with a very large 
epidemic (1981). In contrast, annual costs reported by Suaya 
and others  4   for five countries, Anez and others  26   for Venezuela, 
and Torres and Castro  9   for Nicaragua were lower than those 
in our analysis, but none of these authors corrected for under-
reporting. Comparing the results of different economic stud-
ies is a difficult exercise, requiring the understanding of both 
methodological and epidemiological differences. Our use of 
the same method in all American countries and the consider-
ation of a reference period encompassing both high and low 
incidence years can, therefore, be viewed as a strength. 
  Our estimates of the annual number of DALYs related 
to dengue are consistent with previous reports, such as the 
WHO’s assessment of the 2004 global burden of disease  53  
(73,000 DALYs for the Americas) and the estimate by Hotez 
and others  19   (69,000 DALYs in 2006 for Latin America and 
the Caribbean). Comparing our results with those available 
for individual countries, our estimates are lower than the 
658 DALYs per million inhabitants derived by Meltzer and 
others  35   for Puerto Rico but higher than the 22 DALYs per 
million inhabitants reported by Luz and others  45   for  Brazil, 
 Figure 3.        Annual economic burden in the Americas from 2000 
to 2007 (in 2010 US$).       
 Figure 4.        Variation of total dengue costs according to parameters 
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although the wide range of possible values in this latter analy-
sis included our point estimate. 
  Comparing the human and economic burden of dengue 
with that of other infectious diseases is informative. Dengue 
consequences, measured in DALYs, are substantial but lower 
than the results observed for some other diseases.  53   Hotez and 
others  19   ranked dengue fifth among neglected tropical dis-
eases. Interestingly, Kim and others  36   for rotavirus and Goldie 
and others  37   for HPV also provided a point of comparison 
for countries in the Americas (Bolivia, Cuba, Guayana, Haiti, 
Honduras, and Nicaragua) eligible for Global Alliance for 
Vaccines and Immunization (GAVI) programs. The number 
of DALYs that can be prevented through vaccination against 
rotavirus (50,000) or HPV (31,000) is greater than the number 
of DALYs derived for dengue in our analysis for these GAVI 
countries (8,000), and the total cost of both rotavirus and HPV 
is estimated at I$10 million, which is more than 10-fold lower 
than the cost of dengue in our analysis (I$124 million). DALY 
calculations are, in fact, heavily driven by mortality, which for-
tunately, remains low for dengue (about 100 cases for the six 
GAVI countries). In absence of vaccination and with vector 
control as the only strategy to mitigate the spread of disease, 
dengue causes high incidence and morbidity, which is reflected 
in overall cost of the disease. Despite the lower number of 
DALYs, the potential economic attractiveness of vaccination 
might be as good, if not better, for dengue than for rotavirus 
or HPV. 
  The limitations of our analysis should not be overlooked. 
First, the expansion factors to correct for the underreporting 
of dengue cases are estimations based on limited datasets and 
expert opinion. Despite the unknowns, it is nevertheless criti-
cal to acknowledge underreporting in cost analyses to avoid 
systematically underestimating the disease burden. It is well-
documented that routine surveillance systems, despite their 
critical role in the assessment and monitoring of disease bur-
den, are not designed to comprehensively detect all cases.  56   In 
such situations, extensive sensitivity analysis and conservative 
assumptions are advisable. The comparability of our estima-
tions of dengue incidence in the four regions at high dengue 
risk—from 0.9% to 1.4%—with published data from prospec-
tive studies—0.4–1.8% in Nicaragua  56   and 0.8% in Puerto 
Rico  57  —suggests that our assumed rates of underreporting 
were realistic. 
  The second limitation came from the absence of country-
specific cost data for all American countries, which we man-
aged by extrapolating data between countries in subregions 
and performing sensitivity analysis. Several factors might 
limit the validity of our extrapolation, including differences in 
patient and disease characteristics, differences in the national 
healthcare system, and differences in the overall level of 
costs.  47,  48   We nevertheless attempted to account for these fac-
tors. Specifically, the WHO-CHOICE database  58   was used to 
consider differences in healthcare cost structure not related to 
differences in purchasing power. This goes beyond the usual 
approach based only on the correction of differences in pur-
chasing power. The use of data collected with a consistent 
methodology is an added advantage in that process. 
  The third notable limitation is the exclusion of costs associ-
ated with dengue prevention (i.e., surveillance and vector con-
trol activities). Such costs have been found to add 43% to the 
cost of dengue in Panama,  27   49% in Puerto Rico,  46   and 39% 
in Thailand.  59   Data constraints similarly precluded the consid-
eration of the impact of dengue outbreaks on tourism, poten-
tially an important component.  60   Finally, because the impact is 
 Table 5 
    Aggregate annual costs induced by dengue illness in 2010 US$ (2000–2007)        *     
Area Total costs (millions of I$)
Cost breakdown (%)
Cost per capita Cost per case Ambulatory cases Hospital cases Deaths
North America 5.4 (1.8–10.7) 45.5 (0–83) 54.5 (17–100) 0.0 (0–0) 0.02 (0.01–0.03) $3,154 (1,684–4,138)
Central America and Mexico 669.2 (386.4–1026) 75.5 (56–86) 22.7 (13–41) 1.7 (1–3) 4.82 (2.78–7.39) $538 (384–683)
Andean subregion 803.1 (462.6–1254.7) 68.8 (46–82) 28.5 (15–50) 2.6 (2–5) 6.71 (3.86–10.48) $489 (371–591)
Brazil 1,348.6 (269.9–3076.9) 78.3 (18–95) 19.4 (4–75) 2.1 (1–9) 7.12 (1.43–16.25) $627 (248–878)
Southern cone  †  49.3 (20.6–89) 74.1 (38–90) 24.9 (9–60) 1.1 (1–3) 0.79 (0.33–1.43) $358 (222–441)
Caribbean 335.9 (239.4–449.4) 62.0 (47–73) 30.5 (20–44) 7.3 (5–11) 8.66 (6.17–11.59) $745 (626–854)
The Americas 3,211.4 (1,380.8–5,906.9) 73.7 (36–88) 23.6 (10–59) 2.6 (1.5–6.7) 3.62 (1.56–6.65) $571 (362–752)
    Note that intervals in parentheses show 95% confidence intervals.   
    *     Annual average calculated over the 2000–2007 period.   
  †   Countries  other  than  Brazil.  
 Table 4 
    Annual costs and DALYs induced by dengue illness in the Americas in 2010 US$ (2000–2007)  *     
Area Total costs (millions of US$)
Cost breakdown (%)
Cost per capita Cost per case DALYs Ambulatory cases Hospital cases Deaths
North America 5.4 (1.8–10.7) 45.5 (0–83) 54.5 (17–100) 0.0 (0–0) 0.02 (0.01–0.03) $3,154 (1,684–4,138) 18 (7–35)
Central America 
and Mexico
380.8 (212.1–596.7) 75.6 (56–86) 22.7 (12–41) 1.6 (1–3) 2.74 (1.53–4.3) $307 (210–398) 15,424 (11,353–20,423)
Andean 
subregion
538.6 (271.3–877.5) 68.4 (40–84) 29.2 (14–57) 2.2 (1–4) 4.50 (2.27–7.33) $326 (218–414) 20,223 (13,712–28,872)
Brazil 878.2 (178.8–1996.7) 78.3 (17–95) 19.5 (4–76) 2.0 (1–9) 4.64 (0.94–10.55) $410 (164–577) 26,492 (11,722–52,947)
Southern cone  †  25.4 (10.1–45.8) 74.4 (39–90) 24.5 (9–59) 1.1 (1–3) 0.41 (0.16–0.73) $184 (109–227) 1,658 (856–3,009)
Caribbean 321.4 (224.5–438) 62.2 (47–74) 31.7 (20–46) 6.1 (4–9) 8.29 (5.79–11.29) $713 (592–837) 8,957 (7,430–10,588)
The Americas 2,149.8 (898.4–3,965.4) 72.9 (34–88) 24.4 (10–61) 2.6 (1.5–6.8) 2.42 (1.01–4.47) $382 (236–508) 72,772 (45,080–115,874)
    Note that intervals in parentheses show 95% confidence intervals.   
    *     Annual average calculated over the 2000–2007 period.   
  †   Countries  other  than  Brazil.  206 SHEPARD AND OTHERS
often intangible, our analysis did not factor in the disruption 
to the rest of the health system caused by the seasonal cluster-
ing of dengue. For example, in Venezuela, a dengue epidemic 
country that publishes numbers of cases by week, the highest 
13-week period (August 19 through November 17) contained 
more than three times as many cases (40%) as the lowest 
13-week period (March 4 through June 9; only 12%).  59,  61,  62  
Therefore, our results may still underestimate the overall 
economic consequences of dengue, and the cost components 
excluded from the current analysis deserve study in the future. 
Finally, if the current trend of increasing dengue burden per-
sists, total dengue costs are likely to grow over time, and the 
current estimate will need updating in a few years. 
  The major strength of our analysis is presenting estimates 
of dengue burden for all of the Americas combined as well as 
providing economic data not previously available for a large 
number of countries affected by dengue. The use of a consis-
tent methodology for estimating costs in each country also 
facilitates the comparisons among countries of dengue bur-
den. Our results are conservative, because some important 
dengue-related costs were not included. Nevertheless, these 
results enable a useful comparison of the economic conse-
quences of dengue compared with other infectious diseases. 
The methodology developed here could be applied to dengue 
in other regions or in future updates. Such extensions would 
quantify the evolution of dengue in the Americas over time 
and the comparison of dengue with other conditions. 
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